Literature DB >> 20180063

[Systemic treatment of metastatic prostate cancer].

B Wörmann1, J M Wolff.   

Abstract

Systemic treatment of advanced prostate cancer is multifaceted. First-line therapy is antihormonal treatment with androgen deprivation or antiandrogens. Chemotherapy is effective in hormone refractory (castration resistant) prostate cancer. Alternative and supplementary options include radionuclides, steroids, and symptomatic measures. Use of bisphosphonates is standard in metastatic bone disease. Treatment of patients with metastatic prostate cancer is palliative. The aims are prolongation of overall survival, prolongation of progression-free survival, control and relief of symptoms, and restoration and maintenance of quality of life. Current options allow personalized patient care. New approaches and new drugs will increase the therapeutic possibilities considerably.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20180063     DOI: 10.1007/s00120-010-2238-3

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  30 in total

1.  Randomized, double-blind, placebo-controlled trial of epoetin alfa in men with castration-resistant prostate cancer and anemia.

Authors:  Eric Winquist; Jim A Julian; Malcolm J Moore; Abdenour Nabid; Jinka Sathya; Lori Wood; Peter Venner; Mark Levine
Journal:  J Clin Oncol       Date:  2008-12-22       Impact factor: 44.544

Review 2.  Immunotherapeutics in development for prostate cancer.

Authors:  Andrea L Harzstark; Eric J Small
Journal:  Oncologist       Date:  2009-04-02

3.  Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years.

Authors:  Peter Iversen; Jan-Erik Johansson; Pär Lodding; Timo Kylmälä; Per Lundmo; Peter Klarskov; Teuvo L J Tammela; Ilker Tasdemir; Thomas Morris; Jon Armstrong
Journal:  Scand J Urol Nephrol       Date:  2006

4.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

5.  Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.

Authors:  Celestia S Higano; Paul F Schellhammer; Eric J Small; Patrick A Burch; John Nemunaitis; Lianng Yuh; Nicole Provost; Mark W Frohlich
Journal:  Cancer       Date:  2009-08-15       Impact factor: 6.860

Review 6.  Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis.

Authors:  Marcello Tonelli; Brenda Hemmelgarn; Tony Reiman; Braden Manns; M Neil Reaume; Anita Lloyd; Natasha Wiebe; Scott Klarenbach
Journal:  CMAJ       Date:  2009-04-30       Impact factor: 8.262

Review 7.  [GnRH antagonists--a new therapy option for advanced prostate cancer].

Authors:  J M Wolff
Journal:  Aktuelle Urol       Date:  2009-04-27       Impact factor: 0.658

Review 8.  Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond.

Authors:  Matthew R Smith
Journal:  Urol Oncol       Date:  2008 Jul-Aug       Impact factor: 3.498

Review 9.  Terazosin for benign prostatic hyperplasia.

Authors:  T J Wilt; R W Howe; I R Rutks; R MacDonald
Journal:  Cochrane Database Syst Rev       Date:  2002

10.  Efficacy of low-dose dexamethasone in castration-refractory prostate cancer.

Authors:  Ramachandran Venkitaraman; Karen Thomas; Robert A Huddart; Alan Horwich; David P Dearnaley; Chris C Parker
Journal:  BJU Int       Date:  2007-10-17       Impact factor: 5.588

View more
  1 in total

Review 1.  [Pathophysiology and therapy of castration-resistant prostate cancer].

Authors:  A S Merseburger; M A Kuczyk; J M Wolff
Journal:  Urologe A       Date:  2013-02       Impact factor: 0.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.